Table of Contents
Asian Journal of Neuroscience
Volume 2014, Article ID 181325, 9 pages
Review Article

Clinicotherapeutic Potential of Leptin in Alzheimer’s Disease and Parkinson’s Disease

1Department of Neuroscience, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064, USA
2Department of Biochemistry, Institute of Post-Graduate Medical Education & Research, 244B Acharya J. C. Bose Road, Kolkata 700020, India
3Department of Neuroscience, Burke-Cornell Medical Research Institute, 785 Mamaroneck Avenue, White Plains, NY 10605, USA

Received 29 May 2014; Accepted 21 July 2014; Published 13 August 2014

Academic Editor: Cristoforo Comi

Copyright © 2014 Soumyabrata Munshi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chronic neurodegenerative diseases are a group of devastating neurological disorders that result in significant morbidity and mortality in the elderly population worldwide. Recent researches have shown some interesting associations of the classical antiobesity hormone leptin with two most important neurodegenerative diseases—Alzheimer’s disease (AD) and Parkinson’s disease (PD). Although several clinical studies have found the procognitive and memory-enhancing role of this peptide hormone in leptin-deficient patients, surprisingly it has not been used in any clinical trials involving patients with developing or full-blown neurodegenerative conditions. This review article is an attempt to bring together the existing information about the clinical associations of leptin with AD and PD. It starts with the basic understanding of leptin action in the brain and its derangements in these diseases and eventually discusses the potential of this hormone as a neuroprotective agent in clinical scenario.